NCT05695417View on ClinicalTrials.gov

Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

January 15, 2023

Primary Completion Date

January 31, 2024

Study Completion Date

December 31, 2024

Conditions
Non-proliferative Diabetic Retinopathy
Interventions
DRUG

OTX-TKI

Injection of OTX-TKI

DRUG

Sham

Sham Injection of OTX-TKI

Trial Locations (10)

21740

Ocular Therapeutix, Inc., Hagerstown

30909

Ocular Therapeutix, Inc., Augusta

60439

Ocular Therapeutix, Inc., Lemont

77384

Ocular Therapeutix Inc., The Woodlands

77401

Ocular Therapeutix Inc, Bellaire

78211

Ocular Therapeutix, Inc, San Antonio

78750

Ocular Therapeutiux, Inc., Austin

85053

Ocular Therapeutix Inc, Phoenix

89502

Ocular Therapeutix, Inc., Reno

93308

Ocular Therapeutix, Inc., Bakersfield

Sponsors
All Listed Sponsors
lead

Ocular Therapeutix, Inc.

INDUSTRY

NCT05695417 - Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy | Biotech Hunter | Biotech Hunter